Stock CNTA CENTESSA PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
8.92 USD -0.11% Intraday chart for Centessa Pharmaceuticals plc -15.61% +12.06%
Apr. 24 Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge MT
Apr. 24 Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS MT

Business Summary

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

Number of employees: 76

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
0 nan % 7 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United Kingdom
100.0 %
0 nan % 7 100.0 % -

Managers

Managers TitleAgeSince
Saurabh Saha CEO
 Chief Executive Officer 47 20-12-31
Gregory Mark Weinhoff DFI
 Director of Finance/CFO 53 21-02-28
Ellie Im CTO
 Chief Tech/Sci/R&D Officer - 23-10-02
April Dovholuk COO
 Chief Operating Officer - 23-10-02
David Chao ADM
 Chief Administrative Officer 56 21-03-31
Kristen K. Sheppard IRC
 Investor Relations Contact - 22-05-31
Harris Rotman LAW
 General Counsel - 22-06-30
Patrick Yue PRN
 Corporate Officer/Principal - 23-02-28
Iqbal Hussain LAW
 General Counsel 43 21-01-31
Karen Anderson HRO
 Human Resources Officer 57 22-11-29

Members of the board

Members of the board TitleAgeSince
Mary Lynne Hedley BRD
 Director/Board Member 61 21-02-22
Francesco de Rubertis CHM
 Chairman 54 20-10-31
Brett Zbar BRD
 Director/Board Member 51 20-12-31
Saurabh Saha CEO
 Chief Executive Officer 47 20-12-31
Samarth Kulkarni BRD
 Director/Board Member 45 21-02-22
Arjun Goyal BRD
 Director/Board Member - 20-12-31
Carol Stuckley BRD
 Director/Board Member 68 21-05-16
Mathias Hukkelhoven BRD
 Director/Board Member 70 22-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 100,305,850 88,670,371 ( 88.40 %) 0 88.40 %

Shareholders

NameEquities%Valuation
Medicxi Ventures (Jersey) Ltd.
20.45 %
19,963,157 20.45 % 226 M $
General Atlantic LLC
9.917 %
9,681,818 9.917 % 109 M $
BVF, Inc.
8.988 %
8,774,570 8.988 % 99 M $
EcoR1 Capital, LLC
5.755 %
5,618,779 5.755 % 63 M $
VV Manager LLC
4.027 %
3,931,818 4.027 % 44 M $
OUP Management Co. LLC
3.009 %
2,937,615 3.009 % 33 M $
Adage Capital Partners GP LLC
2.966 %
2,896,128 2.966 % 33 M $
Fidelity Management & Research Co. LLC
2.855 %
2,787,194 2.855 % 31 M $
T Rowe Price Associates, Inc. (13F Subfiler)
2.601 %
2,539,464 2.601 % 29 M $
Octagon Capital Advisors LP
2.110 %
2,060,100 2.110 % 23 M $
NameEquities%Valuation
General Atlantic LLC
10.77 %
9,681,818 10.77 % 109 M $
David Grainger
1.102 %
990,290 1.102 % 11 M $
NXERA PHARMA CO., LTD.
1.034 %
929,353 1.034 % 11 M $
Saurabh Saha
1.008 %
906,187 1.008 % 10 M $
Antoine Yver
0.8710 %
783,066 0.8710 % 9 M $
David Chao
0.3037 %
272,986 0.3037 % 3 M $
Gregory Mark Weinhoff
0.2949 %
265,111 0.2949 % 3 M $
Iqbal Hussain
0.2425 %
218,030 0.2425 % 2 M $
Thomas S. Templeman
0.2094 %
188,244 0.2094 % 2 M $
Tia Bush
0.1892 %
170,064 0.1892 % 2 M $

Company contact information

Centessa Pharmaceuticals Plc

1 Ashley Road 3rd Floor

WA14 2DT, Altrincham

+

http://www.centessa.com
address Centessa Pharmaceuticals plc(CNTA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.92 USD
Average target price
13.6 USD
Spread / Average Target
+52.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CENTESSA PHARMACEUTICALS PLC Stock Centessa Pharmaceuticals plc
+12.06% 991M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CNTA Stock
  4. Company Centessa Pharmaceuticals plc